Un groupe coopérateur engagé dans la recherche sur le lymphome

Production scientifique

Publications 2018

  • Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma
Al Tabaa Y, Tchernonog E, Faurie P, Cottereau AS, Monjanel H, Bonnet A, Le Gouill S, Gyan E, Ghesquieres H, Mariano-Goulart D, Cartron G
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1705-1709. doi: 10.1007/s00259-018-4020-5
  • Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G; Lymphoma Study Association.
Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5
  • Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators.
N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104
  • How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
Gisselbrecht C, Van Den Neste E
Br J Haematol 2018 Sep;182(5):633-643. doi: 10.1111/bjh.15412
  • A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma
Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, Schmitt A, Houot R, Dartigeas C, Pignon JM, Corm S, Banos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Sarkozy C, Damaj G, Feugier P, Fornecker LM, Chabrot C, Dorveaux V, Bouabdallah K, Amorin S, Garidi R, Voillat L, Joly B, Solal Celigny P, Morineau N, Moles MP, Zerazhi H, Fontan J, Arkam Y, Alexis M, Delwail V, Vilque JP, Ysebaert L, Le Gouill S, Callanan MB
Haematologica 2018 Aug 31. pii: haematol.2018.191429. doi: 10.3324/haematol.2018.191429
  • An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
Morschhauser F, Salles G, Le Gouill S, Tilly H, Thieblemont C, Bouabdallah K, Fabiani B, Ménard C, Tarte K, Cartron G, Houot R
Blood. 2018 Aug 1. pii: blood-2018-05-853499. doi: 10.1182/blood-2018-05-853499.
  • Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
Gyan E, Sonet A, Brice P, Anglaret B, Laribi K, Fruchart C, Tilly H, Araujo C, Soubeyran P, Gonzalez H, Morineau N, Nicolas-Virelizier E, Ghesquières H, Salles B, Bouabdallah R, Orfeuvre H, Fahri J, Couturier O, Xerri L, Feugier P; Lymphoma Study Association (LYSA)
Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15513
  • Progression-Free Survival at 24 Months (PFS24) and Subsequent Outcome For Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled On Randomized Clinical Trials.
Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B
Ann. Oncol. 2018 Jun 12. doi: 10.1093/annonc/mdy203.
  • Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from LYSA centers.
Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H.
Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154.
  • NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.
Vo DN, Alexia C, Allende-Vega N, Morschhauser F, Houot R, Menard C, Tarte K, Cartron G, Villalba M.
Oncoimmunology. 2017 Dec 20;7(4):e1409322. doi: 10.1080/2162402X.2017.1409322. eCollection 2018.
  • HLA class I and II diversity contributes to the etiologic heterogeneity of non-Hodgkin lymphoma subtypes
Wang SS, Carrington M, Berndt SI, Slager SL, Bracci PM, Voutsinas J, Cerhan JR, Ekström Smedby K, Hjalgrim H, Vijai J, Morton LM, Vermeulen R, Paltiel O, Vajdic CM, Linet MS, Nieters A, de Sanjosé S, Cozen W, Brown EE, Turner J, Spinelli JJ, Zheng T, Birmann BM, Flowers CR, Becker N, Holly EA, Kane E, Weisenburger D, Maynadie M, Cocco P, Albanes D, Weinstein SJ, Teras LR, Diver WR, Lax SJ, Travis RC, Kaaks R, Riboli E, Benavente Y, Brennan P, McKay JD, Delfau-Larue MH, Link BK, Magnani C, Ennas MG, Latte G, Feldman AL, Wong Doo N, Giles GG, Southey MC, Milne RL, Offit K, Muskinsky J, Arslan AA, Purdue MP, Adami HO, Melbye M, Glimelius B, Conde L, Camp NJ, Glenn M, Curtin K, Clavel J, Monnereau A, Cox DG, Ghesquières H, Salles G, Boffetta P, Foretova L, Staines A, Davis S, Severson RK, Lan Q, Brooks-Wilson A, Smith MT, Roman E, Kricker A, Zhang Y, Kraft P, Chanock SJ, Rothman N, Hartge P, Skibola CF.
Cancer Res. 2018 May 7. pii: canres.2900.2017. doi: 10.1158/0008-5472.CAN-17-2900.
  • Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.
Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B.
Blood. 2018 May 2. pii: blood-2018-02-811174. doi: 10.1182/blood-2018-02-811174.
  • Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
Van den Neste E, André M, Gastinne T, Stamatoullas A, Haioun C, Belhabri A, Reman O, Casasnovas O, Guesquieres H, Verhoef G, Claessen MJ, Poirel HA, Copin MC, Dubois R, Vandenberghe P, Stoian IA, Cottereau AS, Bailly S, Knoops L, Morschhauser F
Haematologica 2018 May;103(5):840-848. doi: 10.3324/haematol.2017.180554
  • How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
Gisselbrecht C, Van Den Neste E.
Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15412.
  • Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma.
Delfau-Larue MH, van der Gucht A, Dupuis J, Jais JP, Nel I, Beldi-Ferchiou A, Hamdane S, Benmaad I, Laboure G, Verret B, Haioun C, Copie-Bergman C, Berriolo-Riedinger A, Robert P, Casasnovas RO, Itti E.
Blood Adv. 2018 Apr 10;2(7):807-816. doi: 10.1182/bloodadvances.2017015164.
  • Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
Maurer MJ, Ghesquières H, Link BK, Jais JP, Habermann TM, Thompson CA, Haioun C, Allmer C, Johnston PB, Delarue R, Micallef IN, Peyrade F, Inwards DJ, Ketterer N, Farooq U, Fitoussi O, Macon WR, Molina TJ, Syrbu S, Feldman AL, Slager SL, Weiner GJ, Ansell SM, Cerhan JR, Salles GA, Witzig TE, Tilly H, Nowakowski GS.
J Clin Oncol. 2018 Apr 19:JCO2017765198. doi: 10.1200/JCO.2017.76.5198
  • A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, da Silva MG, Fitoussi O, Belada D, Maisonneuve H, Intragumtomchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G
Blood 2018 Apr 17. pii: blood-2017-11-816405. doi: 10.1182/blood-2017-11-816405.
  • Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
Cottereau AS, El-Galaly TC, Becker S, Broussais F, Petersen LJ, Bonnet C, Prior JO, Tilly H, Hutchings M, Casasnovas O, Meignan M
J Nucl Med 2018 Apr;59(4):589-595. doi: 10.2967/jnumed.117.193946.
  • Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?
Cottereau AS, Buvat I, Kanoun S, Versari A, Casasnovas O, Chauvie S, Clerc J, Gallamini A, Meignan M.
Eur J Nucl Med Mol Imaging. 2018 Apr 12. doi: 10.1007/s00259-018-4005-4.
  • Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
Deau B, Amorim S, Perrot A, Quittet P, Cornillon J, Chaoui D, Marolleau JP, Oberic L, Le Du K, Fornecker LM, Tournilhac O, Veillard AS, Chaillol I, Robin M, Tamburini J, Brice P
Br J Haematol. 2018 May;181(3):341-349. doi: 10.1111/bjh.15184.
  • RNA fusions involving CD28 are rare in peripheral T-Cell lymphomas and concentrate mainly in those derived from follicular helper T cells.
Vallois D, Dupuy A, Lemonnier F, Allen G, Missiaglia E, Fataccioli V, Ortonne N, Clavert A, Delarue R, Rousselet MC, Fabiani B, Llamas-Gutierrez F, Ogawa S, Thome M, Ko YH, Kataoka K, Gaulard P, de Leval L
Haematologica 2018 Mar 15. pii: haematol.2017.186767

 

  • Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.
Cottereau AS, Versari A, Luminari S, Dupuis J, Chartier L, Casasnovas RO, Berriolo-Riedinger A, Menga M, Haioun C, Tilly H, Tarantino V, Federico M, Salles G, Trotman J, Meignan M
Blood 2018 Mar 20. pii: blood-2017-11-816298. doi: 10.1182/blood-2017-11-816298
  • Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W.
Lancet 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2
  • Prognostic value of baseline metabolic tumor volume in early stage Hodgkin’s lymphoma in the standard arm of H10 trial.
Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R, Bardet S, Castagnoli A, Brice P, Raemaekers J, Deau B, Fortpied C, Raveloarivahy T, Van Zele E, Chartier L, Vander Borght T, Federico M, Hutchings M, Ricardi U, Andre M, Meignan M
Blood 2018 Feb 1. pii: blood-2017-07-795476.
  • Bendamustine-Based conditioning prior to ASCT: Results of a French Multicenter Study of 474 Patients from LYSA Centers.
Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, Fornecker LM, Houot R, Gastinne T, Soussain C, Malak S, Lemal R, Delette C, Ibrahim A, Gac AC, Reboursière E, Vilque JP, Bekadja MA, Casasnovas RO, Gressin R, Guidez S, Coso D, Herbaux C, Bouabdallah K, Durot E, Damaj G.
Am J Hematol 2018 Feb 23. doi: 10.1002/ajh.25077
  • From genetics to the clinic: a translational perspective on follicular lymphoma
Huet S, Sujobert P, Salles G
Nat Rev Cancer. 2018 Feb 9. doi: 10.1038/nrc.2017.127
  • A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L,Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G
Lancet Oncol. 2018 Feb 20. pii: S1470-2045(18)30102-5
  • Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.
Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C; LYSA; lymphoma study association.
Cancer Med 2018 Feb 23. doi: 10.1002/cam4.1139
  • Through the Glass Ceiling.
Tilly H, Salles G, Molina TJ, Casasnovas RO, Morschhauser F, Coiffier B
J Clin Oncol. 2018 Jan 25:JCO2017763961
  • R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma
Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group.
Blood 2018 Jan 11;131(2):174-181

 

Communications en Congrès 2018

  • EHA 2018
    • Oral AHL 2011
    • Oral RELEVANCE : séance présidentielle
    • Oral Refining DLBCL subgroups using integrated analysis of multilevel molecular profiles
    • Poster Allogreffe post-anti-PD1 ATU Nivolumab
  • ASCO 2018
    • Oral AHL 2011
    • Oral RELEVANCE
    • Poster POLARIX
    • Breast Implant Associated-Anaplastic Large Cell Lymphoma
  • SFH 2018
    • Oral Expression protéique p53 et p16 dans le protocole LYMA
    • Poster Efficacicté anti-PD1 Hodgkin
    • Poster Comparaison ZUMA-1 et SCHOLAR-1
    • Poster Rechute DLBCL système nerveux central
    • Poster Facteur de risque rechute SNC

Les missions du LYSA

En savoir +
lymphome

Qu'est ce qu'un lymphome ?

En savoir +

Les recherches du LYSA

En savoir +

Participer à des essais cliniques

En savoir +

Les centres du LYSA

En savoir +

Aider la recherche

En savoir +